MacroGenics Inc. (MGNX) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, MGNX scores 31 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows. Fundamental cash engine scores 4 of 20, reflecting an ROIC of -35% and an FCF yield of 0%. Whale 13F flow scores 7 of 20, covering institutional accumulation and options positioning. Insider conviction scores 5 of 20, covering SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 8 of 20, reflecting a beta of 1.0 and sector sensitivity. Forensic balance sheet scores 7 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 2 out of 9, and a debt-to-equity ratio of 0.5.

For a prospective investor, the weakest pillar is the cash engine, which indicates the business is not currently generating returns on invested capital or free cash flow to support its valuation. The rating's upside drivers are limited to the market-level signals in the news feed and the institutional flow component, which is itself scored at only 7 of 20. Valuation tradeoffs are difficult to assess from this source data because earnings-based multiples are not available in source data, so the stock cannot be benchmarked against earnings. The forensic pillars indicate elevated distress and weak accounting quality signals. Any investor weighing this name should treat the rating as a strong caution flag and examine the reasons for the low pillar scores before drawing conclusions.

Per the SEC financials, revenue was $149.5M in FY 2025 and $150.0M in FY 2024, while operating losses were $-72.8M and $-110.6M respectively. Net income was approximately flat near zero across the reported periods, and free cash flow remained negative in each year. Cash declined from $182.8M in FY 2024 to $57.2M in FY 2025. Per the market data, operating margin is -48.7% and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2 out of 9, and debt-to-equity is 0.5. The Piotroski reading in particular signals weak fundamental quality.

Per the recent news feed, there are six items tagged to MGNX. A Yahoo Finance report asks whether the stock is outpacing medical peers this year, flagged as a market wire item. A GuruFocus report covers promising interim Phase 1 data for an unnamed program. A Stock Titan item, flagged as RISK WATCH, reports that four patients with clear cell gynecologic cancer responded, with all four responses ongoing at cutoff. A MarketBeat item covers short interest and short float as of October 2026. A Mugglehead Investment Magazine report describes a 25% response in the same clear cell gynecologic cancer trial. A ChartMill item lists the stock among top US gainers and losers, flagged as a CATALYST. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.

• What are the company's EPS, P/E, and EV/EBITDA figures, given that all earnings-based valuation multiples are absent from the source data?
• What drove the decline in cash from $182.8M to $57.2M between FY 2024 and FY 2025, and what is the current runway at the FY 2025 free cash flow burn rate?
• What is the debt balance, since the debt field is not available in source data for any period?
• Which specific programs and partnerships generate the $149.5M of FY 2025 revenue, and how durable is that revenue?
• What is the status and timeline of the clear cell gynecologic cancer trial, and how do the reported interim responses compare to prior-stage expectations?